MTSR Metsera, Inc.

Nasdaq metsera.com


$ 63.08 $ 11.52 (22.06 %)    

Thursday, 30-Oct-2025 19:46:23 EDT
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 63.73
$ 62.81
$ 62.95 x 25
$ 68.00 x 10
-- - --
$ 12.30 - $ 66.10
9,514,134
na
6.68B
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid

 pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and pot...

Core News & Articles

- Reuters 

Core News & Articles

Pfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, I...

 metsera-reports-up-to-14-weight-loss-in-phase-2b-obesity-trial

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global P...

Core News & Articles

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateauPotential for best-in-class tolerability with min...

Core News & Articles

Leerink Partners analyst David Risinger downgrades Metsera (NASDAQ:MTSR) from Outperform to Market Perform and lowers the pr...

 pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-matsera-deal

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to ...

Core News & Articles

- Reuters Cites Conf Call

 metsera-stock-surges-over-60-in-monday-pre-market-as-pfizer-reportedly-nears-acquisition-deal-pfe-stock-up-15

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metser...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION